Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 26Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Adenocarcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Melanoma 1Lung Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

sipuleucel-T 2enzalutamide 2gallium 68 PSMA-11 1Vancomycin 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer (mCRPC) × gallium 68 PSMA-11 × 1 year × Clear all
NCT05670106 2026-02-13

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Novartis

Phase 2 Active not recruiting
62 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡